Literature DB >> 26097403

A thermodynamic study of the cyclodextrin-UC781 inclusion complex using a HPLC method.

Haitao Yang1, Michael A Parniak2, Sharon L Hillier3, Lisa C Rohan1.   

Abstract

UC781, a very potent HIV-1 non-nucleoside reverse transcriptase inhibitor with extreme hydrophobicity and poor water solubility, is under development as a topical vaginal microbicide product to prevent HIV transmission. In this study, the thermodynamic behavior of the interaction between UC781 with three cyclodextrins (CDs): β-cyclodextrinCD), hydroxypropyl-β-cyclodextrin (HPβCD) and methyl-β-cyclodextrin (MβCD), was investigated using a reversed-phase HPLC method. A mobile phase consisting of acetonitrile: H2O (30:70) solution containing various CD concentrations was used. The retention time at different temperatures was determined to evaluate the inclusion process. The influence of βCDs on the solubility and hydrophobicity of UC781 was characterized by retention time values. The results showed that the inclusion capacity of cyclodextrins follows the order MβCD > βCD > HPβCD. An enthalpy-entropy compensation effect was also observed. In addition, the results revealed that the change of ΔH is greater than that of ΔS. These results suggested that the complexation of UC781 with βCDs is an enthalpy driven process. The modification on β-cyclodextrin will influence the inclusion process.

Entities:  

Keywords:  Enthalpy; HPLC; Non-nucleoside reverse transcriptase inhibitor (NNRTI); Thermodynamics; UC781; β-cyclodextrin inclusion complex

Year:  2012        PMID: 26097403      PMCID: PMC4472443          DOI: 10.1007/s10847-011-0019-2

Source DB:  PubMed          Journal:  J Incl Phenom Macrocycl Chem        ISSN: 1388-3127            Impact factor:   1.633


  27 in total

1.  The Stability of Cyclodextrin Complexes in Solution.

Authors:  Kenneth A. Connors
Journal:  Chem Rev       Date:  1997-08-05       Impact factor: 60.622

2.  Determination of lipophilicity by reversed-phase high-performance liquid chromatography. Influence of 1-octanol in the mobile phase.

Authors:  Xiangli Liu; Hideji Tanaka; Aiko Yamauchi; Bernard Testa; Hiroshi Chuman
Journal:  J Chromatogr A       Date:  2005-10-14       Impact factor: 4.759

3.  The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase.

Authors:  J Barnard; G Borkow; M A Parniak
Journal:  Biochemistry       Date:  1997-06-24       Impact factor: 3.162

Review 4.  Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization.

Authors:  T Loftsson; M E Brewster
Journal:  J Pharm Sci       Date:  1996-10       Impact factor: 3.534

5.  Cyclodextrins and drug permeability through semi-permeable cellophane membranes.

Authors:  Thorsteinn Loftsson; Már Másson; Hákon H Sigurdsson
Journal:  Int J Pharm       Date:  2002-01-31       Impact factor: 5.875

6.  Improved oral bioavailability of artemisinin through inclusion complexation with beta- and gamma-cyclodextrins.

Authors:  J W Wong; K H Yuen
Journal:  Int J Pharm       Date:  2001-10-04       Impact factor: 5.875

7.  Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction.

Authors:  J P Bader; J B McMahon; R J Schultz; V L Narayanan; J B Pierce; W A Harrison; O S Weislow; C F Midelfort; S F Stinson; M R Boyd
Journal:  Proc Natl Acad Sci U S A       Date:  1991-08-01       Impact factor: 11.205

Review 8.  Enzymatic production of cyclodextrins.

Authors:  A Biwer; G Antranikian; E Heinzle
Journal:  Appl Microbiol Biotechnol       Date:  2002-07-16       Impact factor: 4.813

9.  Characterization of cyclodextrin inclusion complexes of the anti-HIV non-nucleoside reverse transcriptase inhibitor UC781.

Authors:  Haitao Yang; Michael A Parniak; Charles E Isaacs; Sharon L Hillier; Lisa C Rohan
Journal:  AAPS J       Date:  2008-12-17       Impact factor: 4.009

10.  Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes.

Authors:  Norased Nasongkla; Andy F Wiedmann; Andrew Bruening; Meghan Beman; Dale Ray; William G Bornmann; David A Boothman; Jinming Gao
Journal:  Pharm Res       Date:  2003-10       Impact factor: 4.580

View more
  1 in total

1.  A biocompatible poly(amidoamine) (PAMAM) dendrimer octa-substituted with α-cyclodextrin towards the controlled release of doxorubicin hydrochloride from its ferrocenyl prodrug.

Authors:  Artur Kasprzak; Bartłomiej Dabrowski; Agnieszka Zuchowska
Journal:  RSC Adv       Date:  2020-06-19       Impact factor: 4.036

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.